Condition
Epidermal Growth Factor Receptor clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Epidermal Growth Factor Receptor clinical trials that are recruiting, at sites in 3 countries (most in United States (2), Taiwan (2), South Korea (2)). By phase: Phase 2 (2), Phase 1/2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 3Countries
Newest Epidermal Growth Factor Receptor clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| EPI-326 for EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma | Phase 1 | Los Angeles, California and 7 other locations | Recruiting | Mar 10, 2026 |
| Boosting outcomes after osimertinib plus chemotherapy by adding surgery or focal radiation to the primary lung tumor | Phase 2 | Busan | Recruiting | Jul 18, 2025 |
| Investigating a new imaging technique for measuring glycolysis in glioblastoma tumors | Phase 1/2 | Los Angeles, California | Recruiting | Sep 29, 2023 |
| Pemetrexed injected into the spinal fluid for EGFR‑mutant lung cancer that has spread to the leptomeninges. | Phase 2 | Taipei, Taiwan | Recruiting | Apr 10, 2023 |
All recruiting trials (4)
-
EPI-326 for EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma
This phase 1 trial will try EPI-326, a new drug, in people with EGFR-mutant non‑small cell lung cancer or advanced head and neck squamous cell carcinoma to find safe doses, study how the body handles it, and look for early signs it shrinks tumors.
-
Boosting outcomes after osimertinib plus chemotherapy by adding surgery or focal radiation to the primary lung tumor
This trial will test whether giving surgery or focused radiation to the main lung tumor helps people with EGFR-mutant advanced non-small cell lung cancer who have disease controlled after first-line osimertinib plus chemotherapy stay progression-free longer.
-
Investigating a new imaging technique for measuring glycolysis in glioblastoma tumors
This study is testing a new imaging method to see if it can help doctors measure how energy is used in glioblastoma tumors and find hidden cancer cells that are hard to see.
-
Pemetrexed injected into the spinal fluid for EGFR‑mutant lung cancer that has spread to the leptomeninges.
This tests whether giving pemetrexed directly into the spinal fluid helps people with EGFR‑mutant non‑small cell lung cancer whose cancer has spread to the leptomeninges after osimertinib has stopped working.
Related topics
Quick answers
How many Epidermal Growth Factor Receptor clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in United States (2 trials), Taiwan (2 trials), South Korea (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 1/2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.